Thomson, Ph.D., president and chief executive officer of Accuray. ‘While we expect the alliance to generate new sales opportunities for the CyberKnife System, we are equally excited about the potential opportunities that could emerge from our R&D romantic relationship. We think that the mix of radiation treatment and advanced imaging will make a substantial contribution to the continuing future of cancer treatment. Siemens imaging and technical expertise could create exciting possibilities for Accuray to further enhance our placement as the innovator in radiosurgery treatment.’ ‘We are pleased to offer our clients the innovative CyberKnife System through our wide distribution network.AVEO has initiated patient enrollment in TIVO-1, a global Phase 3 medical trial of tivozanib, which is definitely expected to enroll approximately 500 patients with advanced RCC who’ve not received prior VEGF-targeted therapy. TIVO-1 is the first-ever Phase 3 study in RCC designed to evaluate superiority in a head-to-head comparison against a widely prescribed anti-angiogenesis therapy in first-line RCC. The primary endpoint of the trial is usually to compare the PFS of tivozanib vs. Secondary endpoints include overall survival, objective response rate, quality and basic safety of life. This trial happens to be enrolling patients and is being led by Robert Motzer, M.D.